[Edaily Reporter Shin Ha-yeon] On the 10th, NH Investment & Securities projected that #Interrojo’s ODM sales to the U.S. market would expand significantly based on its U.S. Food and Drug Administration (FDA) certification. The firm assessed that the company possesses both growth potential and attractive valuation, driven by improved profitability and the expansion of global distribution channels.

Shim Eui-seop, an analyst at NH Investment & Securities, stated, “The company recently obtained U.S. FDA certification, and with the expansion of certification for additional product lines, growth in ODM sales to the U.S. is expected,” adding, “Along with improved profitability, the company is also pursuing the expansion of global distribution channels.”

Interrojo is a specialized contact lens manufacturer that has proactively launched silicone hydrogel lenses with enhanced oxygen permeability, moving beyond traditional silicone lenses. The company possesses the technological capability to independently design and mass-produce the full range of soft contact lenses, including not only clear lenses but also colored lenses, daily disposable products, and extended-wear lenses.

The company is also expected to accelerate its entry into the U.S. market. Researcher Shim explained, “The company recently obtained FDA 510(k) clearance for its silicone hydrogel contact lenses,” adding, “It received final approval approximately four months after submitting the application to the FDA last February, and is currently pursuing approval for daily disposable and colored lenses in addition to the already approved monthly clear lenses.”

He continued, “These products are also expected to receive approval within the year,” adding, “Based on this approval, we will begin ODM supply to U.S. contact lens companies, expand our lineup of certified products, and increase supply volumes.”

The strategy to expand the global sales network was also viewed positively. Analyst Shim noted, “The company is implementing a multi-faceted sales growth strategy, including renegotiating contracts with overseas partners and expanding distribution channels in various countries.”

He assessed, “With profitability improvements through business restructuring, FDA certification, and revenue growth driven by the expansion of global partnerships, we expect the company to set a new record for performance in 2026,” adding, “With an expected price-to-earnings ratio (PER) of 7.3 times for 2026, the valuation is attractive, making this a good time to take another look at the stock.”